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Abstract: Cancer is one of the most common causes of death among adults. Chemotherapy is
crucial in determining patient survival and quality of life. However, the development of multidrug
resistance (MDR) continues to pose a significant challenge in the management of cancer. In this
study, we analyzed the role of human ribosomal protein uL3 (formerly rpL3) in multidrug resistance.
Our studies revealed that uL3 is a key determinant of multidrug resistance in p53-mutated lung
cancer cells by controlling the cell redox status. We established and characterized a multidrug
resistant Calu-6 cell line. We found that uL3 down-regulation correlates positively with multidrug
resistance. Restoration of the uL3 protein level re-sensitized the resistant cells to the drug by
regulating the reactive oxygen species (ROS) levels, glutathione content, glutamate release, and
cystine uptake. Chromatin immunoprecipitation experiments and luciferase assays demonstrated
that uL3 coordinated the expression of stress-response genes acting as transcriptional repressors of
solute carrier family 7 member 11 (xCT) and glutathione S-transferase α1 (GST-α1), independently of
Nuclear factor erythroid 2-related factor 2 (Nrf2). Altogether our results describe a new function of
uL3 as a regulator of oxidative stress response genes and advance our understanding of the molecular
mechanisms underlying multidrug resistance in cancers.
Keywords: ribosomal protein; nucleolar stress; uL3; multidrug resistance; lung cancer; Nrf2; xCT;
GST-α1; MDR1; chemoresistance
1. Introduction
Lung cancer is one of the most common causes of cancer-related death among adults [1].
Chemotherapy is recognized as an important component of treatment for all stages of lung cancer
and is crucial in determining patient survival and quality of life [2]. However, intrinsic or acquired
multidrug resistance (MDR) is the main reason for tumor recurrence [3]. Therefore, it is crucial to
understand the molecular basis underlying the mechanisms of MDR. Here, we used 5-Fluorouracil
(5-FU) to establish a multidrug resistant lung cell model [4,5].
In addition to its effect on thymidylate synthase inhibition and DNA synthesis, 5-FU may also
influence RNA metabolism [6]. It is known that the nucleolus is a ribosome-supplying organelle,
however a growing body of evidence suggests that the nucleolus plays intriguing novel roles in sensing
cellular stress signals [7]. Under stress conditions, the structure of the nucleolus is perturbed and
some nucleolar proteins, including ribosomal proteins (rp), are released from the nucleolus to the
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nucleoplasm, where they associate with Mouse Double Minute 2 (MDM2) to inhibit its activity and
stabilize p53 [7]. In yeast, it has been reported that the nucleolus can function as an oxidative stress
sensor [8].
It has been demonstrated that some rp play a key role in cell resistance to chemotherapeutic
drugs [9]. Specifically, upon 5-FU induced nucleolar stress, a subset of rp including uL18 (rpL5), uL5
(rpL11), and uL14 (rpL23) are released from the ribosome to activate p53 through MDM2 inhibition [10].
Recently, our studies focused on post-transcriptional regulation [11–14] and extra-ribosomal functions
of ribosomal proteins [11,15]. In particular, we demonstrated that uL3 (formerly rpL3) [16] is involved
in the regulation of its own expression by regulating the splicing of its own transcript [17,18].
In addition, we identified a new molecular pathway activated in the cell response to 5-FU that is
p53-independent but still rp-dependent. We demonstrated that upon ribosomal stress induced by 5-FU,
ribosome free uL3 becomes a regulator of p21 [19,20], cystathionine-β-synthase (CBS) [21–23], and
NFκB [22] expression and mediates apoptosis through the activation of the mitochondrial apoptotic
response pathway. Of note, our data indicated that uL3 status is associated to chemoresistance since
the loss of uL3 makes chemotherapeutic drugs, such as 5-FU, oxaliplatin (L-OHP), Actinomycin D,
and Cisplatin ineffective in colon and lung cancer cells lacking active p53 [21–24]. According to
this, we reported that the resistance of A549 lung cancer cells to Cisplatin correlates to the loss of
uL3 expression [25]. Evidence of the role of some rp mediating drug resistance has been previously
reported. To date, eL36 (rpL36) plays a role in cisplatin resistance in human carcinoma cells [26], the
radiosensitivity in NSCLC (non-small cell lung cancer) cells is regulated by uS3 (rpS3) [27], and eL24
(rpL24) may have effects on drug resistance mechanisms in hepatocellular carcinoma HepG2 cells [28].
In the present study, we identified uL3 (formerly rpL3) as a key molecule conferring multidrug
resistance to lung cancer cells lacking p53 and elucidated the molecular mechanism involved in
this process. We have established and characterized a p53-mutated lung cancer cell line resistant to
5-FU. We have demonstrated that in these cells, uL3 expression is down-regulated upon acquired
multidrug resistance but its restoration re-sensitized the cells to 5-FU through the regulation of
reactive oxygen species (ROS) levels, glutathione (GSH) content, glutamate release, and cystine uptake.
The molecular mechanism by which this occurs involves uL3-mediated control of the stress-response
gene expression. Specifically, uL3 functions as a transcriptional regulator of solute carrier family 7
member 11 (xCT) and glutathione S-transferase α1 (GST-α1), independently of Nuclear factor erythroid
2-related factor 2 (Nrf2).
These data imply that there is a mechanistic link between the response pathway to drug-induced
ribosomal stress and the development of drug resistance and suggest the possibility of targeting uL3 to
modulate the redox status of cancer cells for future therapeutic purposes in order to overcome MDR.
2. Results
2.1. Production of the MDR Resistant p53-Mutated Lung Cancer Cell Line
To explore the mechanisms of MDR, we established a multidrug resistant Calu-6 subline (rCalu-6
cells) derived from the parental Calu-6 sensitive cells. To this aim, Calu-6 cells were continuously
selected with an increasing concentration of 5-FU (from 2.5 to 25 µM) over a period of about 10 months
in order to generate the corresponding age and passage-matched 5-FU resistant cell line designated
rCalu-6. Maintenance of the resistant subline was continued at 20 µM. Figure 1 shows the cell survival
curves of 5-FU sensitive and 5-FU resistant cells, and Calu-6 and rCalu-6 cells, respectively, after
treatment with different concentrations of 5-FU for 48 h. Interestingly, the drug-adapted rCalu-6 cell
line showed a significantly higher IC50 compared with parental Calu-6 cells (52.3 ± 0.02 vs. 4.5 ± 0.08,
respectively). The degree of resistance to 5-FU was evaluated as the ratio of the IC50 values of 5-FU
resistant Calu-6 cells to that of parental cells (Table 1). The results shown in Figure 1A and Table 1
indicate that the Calu-6 subline was successfully established as a 5-FU-resistant lung cancer cell line
with a degree of resistance to 5-FU 11.7-fold higher than parental Calu-6 cells.
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Figure 1. In vitro sensitivity of Calu-6 and rCalu-6 cells to 5-Fluorouracil (5-FU), 
5′-Deoxy-5-fluorouridine (5′-DFUR), Oxaliplatin (L-OHP), and Cisplatin. Cells were cultured with 
increasing concentrations of 5-FU for 48 h and cell growth was assessed by sulforhodamine B (SRB) 
colorimetric assay. Cell growth was expressed as the percentage of control for each time point. ** p < 
0.01, * p < 0.05 vs. untreated cells. The results illustrated in Figures 1–5 are representative of three 
independently performed experiments; error bars represent the standard deviation. 
Table 1. Antiproliferative effect of anticancer drugs on Calu-6 and rCalu-6 cells. The 
tesistance index (RI) is reported as IC50 rCalu-6/IC50 Calu-6. 
Drug 
IC50 (μM) 
r/Calu-6 p-Value (Calu-6 vs. rCalu-6) 
Calu-6 
5-FU 4.5 ± 0.08 52.3 ± 0.02 (RI = 11.7X) <0.01 
5′-DFUR 8.35 ± 0.06 56.7 ± 0.03 (RI = 7X) <0.05 
L-OHP 5 ± 0.07 50 ± 0.03 (RI = 10X) <0.01 
Cisplatin 10 ± 0.02 60 ± 0.05 (RI = 6X) <0.01 
2.2. Cross-Resistance Profiles of rCalu-6 Cells 
Since drug resistance involves the resistance to one drug accompanied by the resistance to 
several other anticancer drugs [29], we evaluated whether rCalu-6 cells acquired cross-resistance to 
other conventional anticancer drugs such as 5′-deoxy-5-fluorouridine (5′-DFUR) (Figure 1B), 
oxaliplatin (L-OHP, Figure 1C) and cisplatin (Figure 1D). Interestingly, cross-resistance to other 
classes of anti-cancer agents was observed, indicating potential multi-resistant phenotypes. The 
degree of resistance of rCalu-6 cells to 5′-DFUR, cisplatin, and L-OHP were 7, 6, and 10-fold higher 
than that of parental sensitive Calu-6 cells, respectively (Table 1). These results indicate that rCalu-6 
cells show resistance to multiple drugs, representing an interesting tool to study MDR in lung 
cancer. 
Figure 1. In vitro sensitivity of Calu-6 and rCalu-6 cells to 5-Fluorouracil (5-FU), 5′-Deoxy-5-
fluorouridine (5′-DFUR), Oxaliplatin (L-OHP), and Cisplatin. Cells were cultured with increasing
concentrations of 5-FU for 48 h and cell growth was assessed by sulforhodamine B (SRB) colorimetric
assay. Cell growth was expressed as the percentage of control for each time point. ** p < 0.01, * p < 0.05
vs. u treate cells. The results illustrated in Figures 1–5 are representative f three independently
performed experiments; error bars represent the standard deviation.
Table 1. Antiproliferative effect of anticancer drugs on Calu-6 and rCalu-6 cells. The tesistance index
(RI) is reported as IC50 rCalu-6/IC50 Calu-6.
Drug
IC50 (µM)
r/Calu-6 p-Value (Calu-6 vs. rCalu-6)
Calu-6
5-FU 4.5 ± 0.08 52.3 ± 0.02 (RI = 11.7X) <0.01
5′-DFUR 8.35 ± 0.06 56.7 ± 0.03 (RI = 7X) <0.05
L-OHP 5 ± 0.07 50 ± 0.03 (RI = 10X) <0.01
Cisplatin 10 ± 0.02 60 ± 0.05 (RI = 6X) <0.01
2.2. Cross-Resistance Profiles of rCalu-6 C lls
Since drug resistance involves the resistance to one drug accompanied by the resistance to
several other anticancer drugs [29], we evaluated whether rCalu-6 cells acquired cross-resistance
to oth r conventio al anticancer drugs such as 5′-deoxy-5-fluorouridine (5′-DFUR) (F ure 1B),
oxalipl tin (L-OHP, Figur 1C) and cisplatin (Figure 1D). Interestingly, cross-resistance to other classes
of anti-cancer agents was observed, indicating pote tial multi-resistant phenot pes. The degree of
resistance of rCalu-6 cells to 5′-DFUR, cisplatin, and L-OHP were 7, 6, and 10-fold higher than that of
parental sensitive Calu-6 cells, respectively (Table 1). These results indicate that rCalu-6 cells show
resistance to multiple drugs, representing an interesting tool to study MDR in lung cancer.
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2.3. Expression Analysis of Genes Related to Drug Resistance in rCalu-6 Cells
According to previous studies, 5-FU resistance is caused by an increase in the 5-FU-degrading
enzyme dihydropyrimidine dehygrogenase (DPYD) and 5-FU-targeting enzyme thymidylate synthase
(TS) [30]. On the other hand, ABC family proteins, such as Multi Drug Reactivity 1 (MDR1), are related
to multiple drug resistance in cancer. We have previously demonstrated that uL3 is able to negatively
control Pgp expression in colon cancer cells by regulation of MDR1 mRNA stability [24]. Moreover,
we also demonstrated that the loss of uL3 and the consequent upregulation of the cystathionine β
synthase (CBS) enzyme correlated with ineffectiveness of 5-FU in lung and colon cancer cell lines [23].
Based on these data, we employed quantitative real-time PCR (qRT-PCR) to assess the expression
profile of TS, DPYD, MDR1, uL3, and CBS in Calu-6 cells and rCalu-6 cells. As shown in Figure 2A,
the resistant cell line showed an increase in MDR1 and CBS mRNA amounts of about 2-fold compared
to those observed in 5-FU sensitive Calu-6 cells. In contrast, for the condition of 5-FU resistance, the
mRNA levels of uL3 were strongly decreased in the resistant cell line compared to control cells.
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Figure 2. Analysis of mRNAs and proteins related to chemoresistance. (A) Total RNA from Calu-6 
and rCalu-6 cells was subjected to Reverse Transcription quantitative Polymerase Chain Reaction 
(RT-qPCR) with primers specific for the indicated mRNAs. The quantification of signals is shown. ** 
p < 0.01, * p < 0.05 vs. mRNA levels in Calu 6 cells set at 1; (B) Protein extracts from Calu-6 and 
rCalu-6 cells were analyzed by Western blotting with antibodies against the indicated proteins. 
β-actin was used as the loading control. The quantification of signals is shown. ** p < 0.01, * p < 0.05 
vs. protein levels in Calu 6 cells set at 1. 
i re . al sis f s and proteins related to chemoresistance. (A) Total RNA from Calu-6 and
rCalu-6 cells was subjected to Reverse Transcription quantitative Polymerase Chain Reaction ( T-qPCR)
with primers specific for the indicated mRNAs. The quantification of signals is shown. ** p < 0.01,
* p < 0.05 vs. mRNA levels in Calu 6 cells set at 1; (B) Protein extracts from Calu-6 and r alu-6 cells
were analyzed by Western blotting with antibodies against the indicated proteins. β-actin was used as
the loading control. The quantification of signals is shown. ** p < 0.01, * p < 0.05 vs. protein levels in
Calu 6 cells set at 1.
Int. J. Mol. Sci. 2017, 18, 547 5 of 16
The mRNA expression of TS and DPYD did not differ between drug resistant and sensitive cell
lines. The expression of these genes at the protein level by Western blot analysis in Calu-6 and rCalu-6
cells was consistent with the mRNA analysis (Figure 2B). The expression levels of eS19 and eL8, two
arbitrary proteins of large and small subunits, respectively, remained unchanged.
2.4. uL3 Mediates Anti-Oxidative Cell Response in rCalu-6 Cells
It is known that the toxicity of antitumor drugs may largely depend on the redox status of the cells.
The observed decreased expression of uL3 in rCalu-6 led us to hypothesize that the levels of uL3 would
be functionally related to ROS production in these cells. To test this hypothesis, we first examined ROS
production in Calu-6 cells and the resistant parental subline. To this aim, Calu-6 and rCalu-6 cells, were
treated with 10 µM 5-FU for 48 h and then the ROS content was determined. As expected, we found
that 5-FU treatment increased ROS production in 5-FU sensitive Calu-6 cells compared to the untreated
cells, while in the resistant rCalu-6 cell line and uL3∆Calu-6 cells, in which uL3 expression was stably
switched off, 5-FU treatment failed to induce ROS production (Figure 3A). Next, we monitored the
levels of intracellular GSH, that is known to play an important role in providing protection against
oxidative damage in the same cells. As shown in Figure 3B, the GSH content in rCalu-6 and uL3∆Calu-6
treated cells was improved compared with that found in the untreated cells. As expected, in treated
Calu-6 cells the level of GSH was significantly lower than in the untreated cells. Next, since cystine
is essential for the generation of GSH, we tested cystine uptake and the release of glutamate in the
same cells. Figure 3C,D shows that cystine uptake and glutamate release were strongly inhibited in
Calu-6 cells after drug treatment. On the contrary, the acquisition of drug resistance was associated to
a significant increase of cystine uptake and glutamate release after 5-FU treatment. These data clearly
suggest that oxidative stress target genes are involved in the molecular mechanism for acquiring
MDR resistance in Calu-6 cells. Interestingly, we demonstrated that the observed alteration in the
cell redox status of resistant cells was specifically mediated by uL3. In fact, the enforced expression
of uL3 in rCalu-6/uL3 was associated to the loss of chemoresistance as observed by the inversion of
the redox status in these cells (Figure 3A–D). Additionally, we performed cell proliferation assays to
evaluate the cell response to 5-FU upon alteration of uL3 status in the cells. As shown in Figure 3E,
the down-regulation of uL3 (rCalu-6 cells and uL3∆Calu-6) was associated to a marked reduced cell
response to 5-FU. The restoration of uL3 (rCalu-6/uL3) re-sensitized rCalu-6 cells to 5-FU causing
a decrease of the percent of cell survival after 5-FU treatment. Interestingly, the over-expression of
eL8 in rCalu-6 cells failed to overcome the chemoresistance and in Calu-6 cells did not affect the cell
response to 5-FU, demonstrating the specificity of uL3 in these processes. The central role of uL3 in
mediating the cell response to 5-FU was also confirmed by the results from the clonogenic survival
assays (Figure 3E).
All together, these results demonstrated that uL3 is essential to mediate the cell response to 5-FU
in Calu-6 cells by control of the cell redox status.
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quantifying ROS production in indicated cell lines after treatment with 5-FU. ** p < 0.01, * p < 0.05
vs. respective untreated cells set at 1; (B) Glutathione (GSH) content in Calu-6 cells and derivative
sublines after treatment with 5-FU. The quantification of signals is shown. ** p < 0.01, * p < 0.05 vs.
respective untreated cells set at 1; (C) Changes in cystine uptake after incubation of i dicated cells with
5-FU. ** p < 0.01, * p < 0.05 vs. resp ctive untreated cells set at 1; (D) Evaluation of glutamate rel ase in
indicated cell lines after tre tment with 5-FU. ** p < 0.01, * p < 0.05 vs. respective untreated cells set
at 1; (E) uL3∆Calu-6, rCalu-6, rCalu-6/uL3, rCalu-6/eL8, Calu-6/eL8 and Calu-6 cells were cultured
with increasing concentrations of 5-FU for 48 h and cell growth was assessed by SRB colorimetric assay.
Cell growth was expressed as the percentage of control for each time point. Ectopic expression of uL3
(rCalu-6/uL3 cells) abolished resistance to 5-FU. ** p < 0.01, * p < 0.05 vs. Calu 6 cells; (F) Representative
image of the clonogenic analysis for cell proliferation of Calu-6, rCalu-6, and rCalu-6/uL3 after
treatment with 10 µM 5-FU for 48 h.
2.5. uL3 Reduces xCT and GST-α1 Expression Levels
To better characterize the mol cular mechanism by which uL3 c ntrols the lteration in c ll-redox
status in MDR resistance, we firstly assessed the intracellular levels of Nrf2 in drug sensitive
and resistant Calu-6 cells, a crucial transcriptional regulator that activates various genes involved
in oxidative stress, together with xCT and GST-α1, as representative Nrf2-regulated antioxidant
defense/drug metabolism genes. To this aim, proteins extracted from Calu-6 treated or not treated
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with 10 µM 5-FU for 48 h, uL3∆Calu-6, and rCalu-6 cells were analyzed by Western blotting with
antibodies against Nrf2, xCT, and GST-A1. Figure 4A shows that in Calu-6 cells, Nrf2 levels are not
significantly modified by 5-FU treatment while xCT and GST-A1 expression levels were markedly
decreased. Interestingly, in uL3∆Calu-6 and rCalu-6 cells, in which uL3 was respectively stably silenced
and significantly down-regulated, we observed a marked increase of the xCT and GST-A1 levels.
On the contrary, Nrf2 levels were not significantly altered in both cell lines and immunoprecipitation
experiments demonstrated the absence of an interaction between Nrf2 and uL3 (Figure S1).
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Figure 4. Influence of uL3 on rf2, xCT, and ST- 1 expression levels in Calu-6 cells and resistant
sublines. (A) Protein extracts fro Calu-6 cells treated or not ith 10 µ 5-FU for 48 h, uL3∆Calu-6
and rCalu-6 cells were analysed by estern blotting with the indicated antibodies. Anti-β-actin was
used as the loading control. The quantification of signals is shown. ** p < 0.01, * p < 0.05 vs. protein
levels in untreated Calu-6 cells set at 1; (B) Total RNA from Calu-6 treated or not with 10 µM 5-FU
for 48 h, uL3∆Calu-6 and rCalu-6 cells were subjected to qPCR with primers specific for the indicated
genes. The quantification of signals is shown. ** p < 0.01,* p < 0.05 vs. mRNA levels in untreated Calu-6
cells set at 1.
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These results clearly demonstrate a central role of uL3 in the regulation of xCT and GST-α1
expression in response to 5-FU treatment and in multidrug resistance.
Next, we analyzed the expression of xCT and GST-α1 at the mRNA level. To this aim, the total
RNA from Calu-6, treated or not treated with 10 µM 5-FU for 48 h, uL3∆Calu-6, and rCalu-6 cells
was isolated and analyzed by quantitative RT-PCR using primers specific for Nrf2, xCT, and GST-α1
mRNAs (Figure 4B). Consistent with the protein analysis, the treatment of Calu-6 cells with 5-FU
resulted in a small reduction of the Nrf2 mRNA level while xCT and GST-α1 mRNA levels were
significantly decreased. Interestingly, in uL3∆Calu-6 and rCalu-6 cells the absence or the reduced
expression of uL3, respectively, was associated to an increase in the xCT and GST-α1 mRNA levels.
The analysis of xCT and GST-α1 mRNA levels in rCalu-6 over-expressing uL3 (rCalu-6/uL3) was
consistent with these data (Figure S2A). In addition, we evaluated the influence of 5-FU on xCT and
GST-α1 mRNA levels in Calu-6, ∆uL3/Calu-6, and rCalu-6 cells. As expected, in the ∆uL3/Calu-6
and rCalu-6 cells, the levels of xCT and GST-α1 were not decreased after 5-FU treatment, in contrast to
Calu-6 cell line (Figure S2B).
Altogether these results indicate that uL3 was necessary for regulating xCT and GST-α1 expression
in response to 5-FU treatment and in drug resistance.
2.6. uL3 Is a Transcriptional Repressor of xCT and GST-α1
Recently, we have demonstrated that after drug treatment the ribosome-free uL3 behaves
as a transcription factor [22], thus we became interested in determining if the uL3-mediated
down-regulation of xCT and GST-α1 expression occurred via the inhibition of gene transcription.
To test the presence of uL3 on xCT and GST-α1 gene promoters, Calu-6 cells untreated or treated with
10 µM 5-FU for 48 h, were collected and subjected to Chromatin immunoprecipitation experiments by
using anti-uL3 antibodies and anti-IgG as negative control.
The presence of uL3 in DNA-immunoprecipitated complexes was assayed by Western blotting
(Figure 5A). qPCR assays on the samples were performed as previously reported [19]. Figure 5A
shows that uL3 was able to bind to xCT and GST-α1 promoters. Interestingly, after 5-FU treatment, this
binding was significantly increased compared to that observed in the control, untreated Calu-6 cells.
Next, to test the role of uL3 on xCT and GST-α1 promoter activities in the response to drug
exposure and in the condition of acquired MDR resistance, we performed reporter luciferase assays.
To this aim, Calu-6 cells untreated or treated with 10 µM 5-FU, rCalu-6, and uL3∆Calu-6 cells were
transiently transfected with the xCT (Figure 5B) or GST-α1 (Figure 5C) promoter luciferase reporter
constructs. Figure 5B,C shows that 5-FU treatment significantly reduced xCT and GST-α1 promoter
activity in Calu-6 cells. On the contrary, the transcriptional activity of these promoters was greatly
increased in the condition of uL3 silencing (uL3∆Calu-6 cells) and in rCalu-6 cells where uL3 expression
was down-regulated. To demonstrate that the observed up-regulation of xCT and GST-α1 promoter
activity in rCalu-6 and uL3∆Calu-6 cells was specifically mediated by uL3 and independent from
Nrf2, we performed analogous experiments in the conditions of Nrf2 silencing or uL3 overexpression.
As shown in Figure 5B,C, Nrf2 depletion did not cause any alteration on xCT or GST-α1 promoter
activities. Ectopic expression of uL3 dramatically reduced xCT and GST-α1 promoter trans-activation.
These results strongly indicate that uL3 is an important player in the transcriptional regulation of xCT
and GST-α1 genes, acting as a negative regulator of their expression independently of Nrf2.
Int. J. Mol. Sci. 2017, 18, 547 9 of 16I t. J. ol. ci. 2017, 18, 547  9 f 16 
 
Figure 5. Analysis of the interaction between uL3 and xCT and GST-α1 gene promoters. (A) Protein 
samples of DNA-uL3 or DNA-IgG immunocomplexes from Calu-6 cells untreated or treated with 10 
µM 5-FU for 48 h were analysed by Western blotting with antibodies against uL3. Note the absence 
of signal in the DNA-IgG immunocomplex. The same DNA-immunoprecipitates were subjected to 
qPCR with primers specific for xCT or GST-α1 gene promoters. The quantification of signals is 
shown. *p < 0.05 vs. DNA levels in untreated cells set at 1. Calu-6 cells treated or not treated with 10 
µM 5-FU for 48 h, uL3ΔCalu-6 and rCalu-6 cells were transiently transfected with (B) xCT promoter 
luciferase reporter plasmid or (C) GST-α1 promoter luciferase reporter plasmid in presence or 
absence of Nrf2 siRNA or pHA-uL3 plasmid. Analysis of the relative luciferase activity, normalized 
against Renilla Luciferase (pRL) activity, of the samples is shown. ** p < 0.01, * p < 0.05 vs. untreated 
Calu-6 cells set at 1. 
3. Discussion 
In this study, we used human Calu-6 cells as a model system to establish a p53-mutated 
multidrug resistant lung cancer cell line. By the stepwise increase of the 5-FU concentration in the 
growth medium and selection of drug-resistance colonies for ten months, we successfully 
established a 5-FU resistant cell line, rCalu-6, with a resistance index of 11.7. In addition, rCalu-6 
cells acquired cross-resistance to L-OHP and cisplatin. To the best of our knowledge, this is the first 
study on the production of a multidrug resistant Calu-6 cell line. This should be useful to study the 
mechanisms underlying drug resistance of p53 mutated lung cancer. 
The determinants of the resistance mechanisms to 5-FU include the enzymes involved in the 
5-FU metabolism pathway [30]. To exert its cytotoxic effects, 5-FU is converted to its active 
metabolites by several enzymes and the levels of these enzymes have been associated with 5-FU 
sensitivity [6]. Previous results reported that the enhanced expression of dihydropyrimidine 
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samples of DNA-uL3 or DNA-IgG immunocomplexes from Calu-6 cells untreated or treated with
10 µM 5-FU for 48 h were analysed by Western blotting with antibodies against uL3. Note the absence
of signal in the DNA-IgG immunocomplex. The same DNA-immunoprecipitates were subjected to
qPCR with primers specific for xCT or GST-α1 gene promoters. The quantification of signals is shown.
* p < 0.05 vs. DNA levels in untreated cells set at 1. Calu-6 cells treated or not treated with 10 µM 5-FU
for 48 h, uL3∆Calu-6 and rCalu-6 cells were transiently transfected with (B) xCT promoter luciferase
reporter plasmid or (C) GST-α1 promoter luciferase reporter plasmid in presence or absence of Nrf2
siRNA or pHA-uL3 plasmid. Analysis of the relative luciferase activity, normalized against Renilla
Luciferase (pRL) activity, of the samples is shown. ** p < 0.01, * p < 0.05 vs. untreated Calu-6 cells set
at 1.
3. Discussion
In this study, we used human Calu-6 cells as a model system to establish a p53-mutated multidrug
resistant lung cancer cell line. By the stepwise increase of the 5-FU concentration in the growth medium
and selection of drug-resistance colonies for ten months, we successfully established a 5-FU resistant
cell line, rCalu-6, with a resistance index of 11.7. In addition, rCalu-6 cells acquired cross-resistance
to L-OHP and cisplatin. To the best of our knowledge, this is the first study on the production of a
multidrug resistant Calu-6 cell line. This should be useful to study the mechanisms underlying drug
resistance of p53 mutated lung cancer.
The determinants of the resistance mechanisms to 5-FU include the enzymes involved in the 5-FU
metabolism pathway [30]. To exert its cytotoxic effects, 5-FU is converted to its active metabolites
by several enzymes and the levels of these enzymes have been associated with 5-FU sensitivity [6].
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Previous results reported that the enhanced expression of dihydropyrimidine dehygrogenase (DPYD)
and thymidylate synthase (TS), a 5-FU-degrading enzyme and a 5-FU-targeting enzyme, respectively,
correlated with the development of 5-FU resistance [30]. However, we found that the expression of
DPYD and TS was not enhanced in rCalu-6 cells. This suggests that the mechanisms of 5-FU resistance
of rCalu-6 cells differ from those generally reported. Interestingly, the acquired drug resistance was
associated to the modification of uL3 expression resulting in a decrease of its intracellular amount.
We have also previously observed a reduction of uL3 levels in Cisplatin resistant A549 cells [25] that,
unlike Calu-6 cells, are proficient for p53, suggesting that the loss of uL3 could be considered a general
mechanism of multidrug resistance independent of p53 status. Furthermore, we demonstrated that
the loss of uL3 was associated with the up-regulation of the MDR1 mRNA level and Pgp transporter
encoded by MDR1 in colon cancer cells [24]. According to this, the multidrug resistance in rCalu-6
cells is associated to the high expression of the human MDR1 gene and the Pgp protein levels.
It is known that the toxicity of antitumor drugs may largely depend on the intracellular level of
reduced GSH that represents the first line antioxidative defense mechanism [31]. Increased resistance
to cancer chemotherapeutic agents is often associated to elevated levels of GSH due to the protective
conjugation and detoxification effects of GSH. To date, it has been demonstrated that the increase
of GSH concentration or GST expression are linked to chemoresistance pathways in human breast
cancer cells [32]. Pathways involved in GSH production and regeneration are controlled by Nrf2, a
crucial regulator of the expression of different genes involved in oxidative stress response and drug
resistance [33–35]. In order to evaluate the role of the GSH/GST system in rCalu-6 cells, we monitored
the levels of intracellular GSH in these cells and in its parent cell line. rCalu-6 cells were shown to
have higher GSH levels than the sensitive Calu-6 cells after 5-FU treatment. These effects are possibly
mediated through up-regulated expression of xCT, causing an increase of the GSH level and inducing
the antioxidative defense. xCT and Cystathionine gamma-lyase (CSE) are two important providers
of intracellular cysteine, the precursor for the generation of GSH. xCT is the catalytic light chain of
system xc− cystine/glutamate antiporter, an Na+-independent heterodimeric amino-acid transport
system that functions as the exchange system for the uptake of extracellular cystine in exchange for the
release of intracellular glutamate, at a 1:1 ratio [36]. Once inside the cells, cystine is rapidly reduced to
cysteine, the rate-limiting substrate for GSH synthesis involved in many physiological processes [37].
Our data showed that in rCalu-6 cells the cystine uptake and glutamate release were strongly increased,
suggesting that oxidative stress target genes are involved in the molecular mechanism for acquiring
multidrug resistance. We have previously demonstrated that uL3 potentiates the cytotoxicity of
5-FU [20–23] and we have also studied the effect of the 5-FU/uL3 combination by using specific
delivery systems [38].
Of note, when uL3 was restored, rCalu-6 cells were resensitized to 5-FU, revealing that the
restoration of uL3 could be a strategy for reversing 5-FU resistance and to resensitize 5-FU resistant
tumors lacking p53 and uL3. Analysis of xCT and GST-α1 mRNA levels reveales that the transcription
of these genes is strongly up-regulated upon multidrug acquired resistance. In rCalu-6 cells, the
down-regulation of uL3 is associated to an increase in xCT and GST-α1 gene promoter activity.
These two genes are known targets of Nrf2. The unchanged expression of Nrf2 in rCalu-6 and the
absence of an interaction between Nrf2 and uL3 (Figure S1) suggest an Nrf2-independent regulation
of xCT and GST-α1 gene expression in our experimental conditions. Accordingly, Nrf2 silencing
in rCalu-6 cells did not cause any alteration on xCT and GST-α1 promoter activity compared to
cells expressing Nrf2. All together, these results indicate that uL3 controls the transcription of
these genes independently of Nrf2. Although it is well established that cystine and glutamate are
substrates of system xc-, it has been recently demonstrated that cystathionine is a novel substrate
of the cystine/glutamate transporter [39]. Cystathionine-β-synthase (CBS), a key enzyme in the
trans-sulfuration metabolic pathway involved in the modulation of H2S production [40,41], converts
homocysteine to cystathionine, which is converted by CSE to cysteine required for synthesis of the
antioxidant glutathione GSH [37]. Silencing CBS severely reduces cellular GSH levels [42]. We have
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previously demonstrated that uL3 is a negative regulator of CBS expression both at the transcriptional
and post-translational levels [23]. rCalu-6 cells express low level of uL3 and high level of CBS. It is
plausible that the observed increase of cellular GSH levels in rCalu-6 cells was also due to the loss of
the CBS inhibitor uL3 with consequent activation of the trans-sulfuration pathway via CBS that lead to
increased availability of the GSH precursor cysteine.
All together, our results led us to propose a model by which upon acquired resistance, the
activation of the defense response depends on the uL3 status (Figure 6). In particular, in the condition
of multidrug resistance, the production of uL3 is down-regulated and the expression of stress-response
genes is activated. Specifically, the binding of uL3 to xCT and GST-α1 gene promoters decreases and, as
a consequence, its inhibitory activity on these two promoters is suppressed. This represents an indirect
way to potentiate the expression of antioxidant genes and activate the defense response. On the one
hand, overexpression of the xCT light chain and the consequent increased activity of the antiporter
system xc- and, on the other hand, the activation of the trans-sulfuration pathway via CBS induced
by lower levels of uL3 [22], lead to increased availability of Cysteine, a GSH precursor crucial for
cell stress response. In addition, uL3 down-regulation positively associated to the up-regulation of
Pgp-expression, contributing to the efflux mediated resistance (Figure 6).
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4. Materials and Methods 
4.1. Cell Cultures, Drug Treatment, and Production of Multidrug Resistant Calu-6 Cells 
Human Calu-6 were cultured as previously described [43]. The uL3ΔCalu-6 cell line was 
obtained from Calu-6 cells by transfecting 2 µg of shRNA uL3 plasmid [21] by using Lipofectamin 
2000 (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
The multidrug resistant Calu-6 cell line (rCalu-6) was established from Calu-6 cells by 
continuous exposure to increasing concentrations of 5-FU (from 2.5 to 25 µM). rCalu-6 cells were 
then maintained in the presence of 20 µM 5-FU. 
For drug treatments, rCalu-6 cells were grown in medium without 5-FU for 2 weeks before 
5-FU addition. 
4.2. Cell Viability Assay and Clonogenic Assay 
The Sulforhodamine B (SRB) colorimetric assay for cell viability of Calu-6 and rCalu-6 cells and 
the clonogenic assay were performed as previously described [25]. 
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4.2. Cell Viability Assay and Clonogenic Assay
The Sulforhodamine B (SRB) colorimetric assay for cell viability of Calu-6 and rCalu-6 cells and
the clonogenic assay were performed as previously described [25].
4.3. Glutathione Measurement
Intracellular GSH concentration was measured using a commercially available kit (Chemicon,
Temecula, CA, USA) according to the manufacturer’s protocol.
4.4. Glutamate Analysis
Glutamate in the cell medium was assayed with Amplex Red assay kits (catalog number: A-12,221,
Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. All treatments were
performed in serum-free and L-glutamine-free MEM (Invitrogen).
4.5. Cystine Uptake
Cystine uptake was performed as previously described [44] by using 50 µm L-[35S]-Cystine
(specific activity 40 mCi/mmol).
4.6. Reactive Oxygen Species (ROS) Assay
Cells were seeded at a density of 1 × 104 in 96-well clear bottom black plates, allowed to
equilibrate overnight, and were starved in serum free medium for 24 h followed by treatments.
Intracelluar ROS levels were determined by using the Cell Meter™ Fluorimetric Intracellular Total
ROS Activity Assay Kit*Red Fluorescence according to the manufacturer’s guideline (catalog number:
22901, AAT Bioquest®, Sunnyvale, CA, USA).
4.7. DNA Constructs, siRNA, and Transfection
DNA constructs containing x-CT and GST-α1 promoters, the plasmid encoding Flag-Nrf2, and the
plasmid encoding uL3-HA (pHA-uL3) and eL8 (pHA-eL8) were already available [21]. siRNA against
Nrf2 was purchased by Santa Cruz Biotechnology (catalog number: sc-37030, Santa Cruz, CA, USA).
Transfections were performed as previously described [45].
4.8. Dual Luciferase Assays
The luciferase assay was performed with a Dual-Luciferase reporter assay system (Promega,
Madison, WI, USA) according to the manufacturer’s instructions. The firefly luciferase activity was
normalized to Renilla internal control luminescence.
4.9. Chromatin Immunoprecipitation
The chromatin immunoprecipitation assay was performed as previously reported [19].
4.10. RNA Isolation, RT, and Quantitative Real-Time PCR
Total RNA from the cells was extracted as previously reported [46]. RT-qPCR was performed
as previously reported [19]. The primers used for RT-qPCR were the following: TS (Forward:
5′-TTACCTGAATCACATCGAGC-3′ and Reverse: 5′-ATATCCTTCGAGCTCCTTTG-3′); DPYD
(Forward: 5′-GTTCTGGCTACCAGGCTAT-3′ and Reverse: 5′-CATAAGGTGTTGTCCTGGAA-3′); uL3
(Forward: 5′-CAAAGGCTACAAAGGGGT-3′ and Reverse: 5′-CTCAGTGCGGTGATGGTAG-3′); MDR1
(Forward: 5′-ATGCCTTCATCGAGTCACTG-3′ and Reverse: 5′-TAACAAGGGCACGAGCTATG-3′);
Nrf2 (Forward: 5′-GAGAGCCCAGTCTTCATTGC-3′ and Reverse: 5′-TGCTCAATGTCCTGTTGCAT-3);
xCT (Forward: 5′-AAACTTGCTAAGCTCTGTGTTGG-3′, Reverse: 5′-CACATCACATGTTTGTACA
CTCG-3′); GST-α1 (Forward: 5′-CAGCAAGTGCCAATGGTTGA-3′ and Reverse: 5′-TATTTGCTG
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GCAATGTAGTTGAGAA-3′); β-actin (Forward: 5′ GGCGGCACCACCATGTACCCT-3′ and Reverse:
5′-AGGGGCCGGACTCGTCATACT-3′). The primers used for CBS were previously reported [22].
The association of uL3 with endogenous x-CT and GST-α1 promoters was measured by qPCR on
immunoprecipitated chromatin as previously described [47].
The PCR products were run on agarose gels and visualized by ethidium bromide staining.
4.11. Western Blot Analysis
Western blotting analysis was performed as previously reported [48]. The membranes were
incubated with anti-uL3 and anti-eL8 (Primm, Milan, Italy), anti-xCT and anti-GST-A1, anti-TS,
anti-DPYD and anti-Pgp (Abcam, Cambridge, MA, USA), anti-eS19 (Sigma-Aldrich, St Louis, MO,
USA), anti-CBS, and anti-β-actin (Santa Cruz Biotechnology). Proteins were visualized with enhanced
chemiluminescence [49]. Densitometric analysis was carried out using ImageJ software (Image 1.49v,
available on: http://imagej.nih.gov/ij, National Institutes of Health, Bethesda, MD, USA).
4.12. Immunoprecipitation Assay
The immunoprecipitation assay was performed as previously described [50] by using anti-Flag
(Santa Cruz Biotechnology). The beads were washed and boiled in the SDS sample buffer. The eluted
proteins were loaded on 12% SDS-PAGE and analyzed by Western blotting.
4.13. Statistical Analysis
Statistical analysis was performed as previously reported [51]. Statistical comparisons were made
by Student’s t-test and one-way ANOVA. p < 0.05 was considered significant, p < 0.01 was considered
highly significant.
5. Conclusions
In conclusion, in this study we provide new insights concerning a rational applicability of the
combined treatment based on 5-FU plus uL3 [24] as an individualized therapy for tumors lacking uL3,
in an attempt to overcome drug resistance and yield better clinical outcomes.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/547/s1.
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